Italy Leads European Push Into Conditional Reimbursement
Executive Summary
Italy claims to have pushed farther into managed entry agreements than other European countries with strong clawback provisions on new drugs – particularly cancer drugs – if they don't work as well as their manufacturers claim. The financial clawbacks are supported by extensive outcome data collection across the country's twenty regions.
You may also be interested in...
EMA Director-Nominee Guido Rasi Brings Track Record For Repairing Regulatory Agency Reputation
Rasi leads the Italian Medicines Agency, an agency also known for conditional reimbursement agreements.
EMA Director-Nominee Guido Rasi Brings Track Record For Repairing Regulatory Agency Reputation
Rasi leads the Italian Medicines Agency, an agency also known for conditional reimbursement agreements.
Celgene Ups Vidaza Discount To Gain Positive NICE Recommendation
U.K. cost-watchdog NICE recommends reimbursement for Celgene's Vidaza after the company offers a steeper discount.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: